Johnson & Johnson/$JNJ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Ticker
$JNJ
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
138,100
ISIN
US4781601046
Website
JNJ Metrics
BasicAdvanced
$366B
16.92
$8.98
0.48
$5.02
3.42%
Price and volume
Market cap
$366B
Beta
0.48
52-week high
$169.99
52-week low
$140.68
Average daily volume
8.2M
Dividend rate
$5.02
Financial strength
Current ratio
1.257
Quick ratio
0.963
Long term debt to equity
49.104
Total debt to equity
52.922
Dividend payout ratio (TTM)
54.76%
Interest coverage (TTM)
30.08%
Profitability
EBITDA (TTM)
30,025
Gross margin (TTM)
68.82%
Net profit margin (TTM)
24.41%
Operating margin (TTM)
25.44%
Effective tax rate (TTM)
18.02%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
7.77%
Return on equity (TTM)
29.45%
Valuation
Price to earnings (TTM)
16.918
Price to revenue (TTM)
4.096
Price to book
4.68
Price to tangible book (TTM)
-35.43
Price to free cash flow (TTM)
19.699
Free cash flow yield (TTM)
5.08%
Free cash flow per share (TTM)
771.65%
Dividend yield (TTM)
3.30%
Forward dividend yield
3.42%
Growth
Revenue change (TTM)
4.30%
Earnings per share change (TTM)
-41.22%
3-year revenue growth (CAGR)
-1.99%
10-year revenue growth (CAGR)
1.96%
3-year earnings per share growth (CAGR)
6.59%
10-year earnings per share growth (CAGR)
4.86%
3-year dividend per share growth (CAGR)
5.37%
10-year dividend per share growth (CAGR)
5.88%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
Bulls say / Bears say
Johnson & Johnson's first-quarter 2025 earnings exceeded Wall Street expectations, driven by a 20% increase in Darzalex sales to $3.24 billion, highlighting strong performance in its oncology segment. (reuters.com)
The company raised its full-year 2025 sales forecast by $700 million to $91.6-$92.4 billion, reflecting confidence in sustained growth and successful integration of recent acquisitions. (reuters.com)
Analysts maintain a 'Moderate Buy' consensus rating for Johnson & Johnson, with an average price target of $170.88, indicating positive sentiment and potential upside for the stock. (marketbeat.com)
Johnson & Johnson faces potential revenue declines due to biosimilar competition, as evidenced by a 33% drop in Stelara sales in Q1 2025. (reuters.com)
The company anticipates approximately $400 million in tariff-related impacts on its medical device segment, which could pressure profit margins. (reuters.com)
Recent legal challenges, including a lawsuit against Samsung Bioepis over a Stelara biosimilar, may lead to increased litigation costs and market uncertainty. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
JNJ News
AllArticlesVideos
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit
Business Wire·1 week ago
Smart Moves With $5,000: Dividend Stocks to Own Amid Market Chaos
24/7 Wall Street·1 week ago
Johnson & Johnson CEO: “We're in the Golden Era of Medical Innovation”
Bloomberg Markets and Finance·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Johnson & Johnson stock?
Johnson & Johnson (JNJ) has a market cap of $366B as of June 27, 2025.
What is the P/E ratio for Johnson & Johnson stock?
The price to earnings (P/E) ratio for Johnson & Johnson (JNJ) stock is 16.92 as of June 27, 2025.
Does Johnson & Johnson stock pay dividends?
Yes, the Johnson & Johnson (JNJ) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $5.02 and the yield is 3.42%. Johnson & Johnson has a payout ratio of 54.76% on a trailing twelve-month basis.
When is the next Johnson & Johnson dividend payment date?
The next Johnson & Johnson (JNJ) dividend payment date is unconfirmed.
What is the beta indicator for Johnson & Johnson?
Johnson & Johnson (JNJ) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.